ISSN 2348-0319 International Journal of Innovative and Applied Research [2023]
(Volume 11, Issue 12)
41-46

Journal home page: http://www.journalijiar.com

INTERNATIONAL JOURNAL
OF INNOVATIVE AND APPLIED RESEARCH

RESEARCH ARTICLE

Article DOI: 10.58538/IJIAR/2060
DOI URL: *http://dx.doi.org/10.58538/IJIAR/2060*

LIFESTYLE, GENETICS AND SICKLE CELL ANEMIA: UNVEILING THE INTERPLAY OF RISK FACTORS

Emmanuel Ifeanyi Obeagu[1], Esther Ugo Alum[2,3], Getrude Uzoma Obeagu[4] and Okechukwu P.C. Ugwu[2]

1. Department of Medical Laboratory Science, Kampala International University, Uganda.
2. Department of Publications and Extension, Kampala International University, P. O. Box 20000, Uganda.
3. Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria, 0000-0003-4105-8615.
4. School of Nursing Science, Kampala International University, Uganda.

Manuscript Info

Manuscript History
Received: 01 November 2023
Final Accepted: 11 December 2023
Published: December 2023

Keywords:
Sickle Cell Anemia, Genetic Predisposition, Environmental Influences, Lifestyle Factors, Disease Management, Comprehensive Approach

Abstract

Sickle cell anemia (SCA) stands as a paradigm of the intricate interplay between genetic predisposition, environmental influences, and lifestyle factors shaping the complexity of this hemoglobinopathy. This comprehensive review endeavors to elucidate the multifaceted relationship between genetic determinants, environmental triggers, and individual lifestyle choices in the genesis, progression, and management of SCA. Genetically, SCA is rooted in mutations within the HBB gene, culminating in the production of aberrant hemoglobin and the characteristic sickled erythrocytes. This section scrutinizes the myriad of genetic variations, emphasizing their implications in disease severity and phenotypic diversity. The review further navigates the landscape of genetic modifiers, exploring their nuanced influence on disease manifestation among carriers of the sickle cell trait. Environmental determinants play a pivotal role in modulating the clinical course of SCA. Geographical disparities, climatic variations, prevalence of infections, and socio-economic factors intricately intertwine to influence disease prevalence, complications, and healthcare accessibility. This review meticulously examines the multifaceted impact of these environmental factors on the disease landscape. Moreover, lifestyle choices wield substantial influence over disease management and outcomes. Balanced nutrition, hydration, physical activity, and psychosocial well-being significantly impact disease severity and crisis occurrence. This section delves into the effects of lifestyle modifications, elucidating their role in minimizing complications and enhancing the quality of life for individuals navigating the challenges of SCA. This paper underscores the synergistic interplay of genetics, environmental influences, and lifestyle factors in sculpting the multifaceted nature of sickle cell anemia. Recognizing these intricate interactions provides a holistic framework for devising personalized management strategies and therapeutic interventions. The synthesis of these elements emphasizes the necessity of a comprehensive approach in unraveling the complexities of SCA and advancing tailored care for affected individuals.

***Corresponding Author:-** **Emmanuel Ifeanyi Obeagu,** *Department of Medical Laboratory Science, Kampala International University, Uganda.*

Introduction:-

Sickle cell anemia (SCA) stands as a quintessential example of a multifaceted genetic disorder, intricately influenced by environmental triggers and individual lifestyle choices [1-5]. Characterized by a single point mutation in the HBB gene, this hereditary hemoglobinopathy manifests with diverse clinical presentations, ranging from asymptomatic carriers to individuals experiencing recurrent vaso-occlusive crises and chronic complications. While the genetic underpinnings of SCA are well-documented, the synergistic interplay of genetic predisposition with environmental and lifestyle factors remains a pivotal area necessitating comprehensive exploration [6-11].The genetic basis of SCA is rooted in the substitution of a single amino acid in the beta-globin chain, leading to the production of abnormal hemoglobin and the distinctive sickled morphology of red blood cells. Yet, the vast heterogeneity observed in disease severity and clinical manifestations among individuals harboring the same genetic mutation prompts a deeper investigation into additional factors modulating disease expression [12-16].

Genetic modifiers and coinheritance of other genetic variants intricately contribute to the phenotypic diversity observed in SCA, shedding light on the complexity of disease manifestation beyond the primary mutation. Furthermore, the influence of environmental determinants, encompassing geographical variations, climatic conditions, prevalence of infections, and socio-economic factors, adds layers of complexity to the disease landscape, influencing disease prevalence, complications, and healthcare accessibility [17-21].In parallel, lifestyle choices wield significant influence over disease management and outcomes. Nutrition, hydration, physical activity, and psychosocial well-being constitute integral components in modulating disease severity, crisis frequency, and overall quality of life for individuals navigating the challenges of SCA.

Genetic Predisposition and Disease Pathogenesis

Sickle cell anemia (SCA) stands as a paradigmatic example of a hereditary disorder heavily influenced by genetic factors, chiefly rooted in mutations within the HBB gene encoding beta-globin. The substitution of a single nucleotide in this gene results in the production of abnormal hemoglobin (HbS) and the consequential sickling of red blood cells under conditions of reduced oxygen tension, instigating the hallmark clinical manifestations of the disease [22-27].The intricate genetic landscape of SCA extends beyond the primary HBB mutation, encompassing an array of genetic modifiers that intricately modulate disease severity and phenotypic variability. Notably, fetal hemoglobin (HbF) levels, mediated by genetic variations influencing its expression, exert a mitigating effect on disease severity. Individuals with elevated HbF levels often exhibit milder symptoms due to its ability to inhibit polymerization of sickle hemoglobin [28-32].Additionally, coinheritance of other genetic variants, such as alpha-globin gene variants or genetic modifiers influencing hemoglobin production, further contribute to the heterogeneous clinical presentations observed among individuals carrying the sickle cell trait. The interaction between these genetic elements forms a complex network that influences disease severity, complications, and response to therapeutic interventions [33-36].The pathogenesis of SCA involves a cascade of events initiated by the abnormal sickle hemoglobin. The characteristic sickling of red blood cells induces vaso-occlusion, leading to tissue ischemia, organ damage, and recurrent painful crises. Moreover, the altered rheological properties of sickled cells predispose affected individuals to chronic hemolytic anemia, increased susceptibility to infections, and a spectrum of end-organ complications [37-39].The elucidation of the genetic underpinnings and disease pathogenesis in SCA has paved the way for targeted therapeutic interventions. Approaches aiming to elevate HbF levels, such as hydroxyurea therapy, have shown promise in ameliorating disease severity by reducing sickling episodes and complications. Emerging gene therapy and gene editing techniques offer potential avenues for correcting the underlying genetic defect, holding promise for potential cures and transformative treatments for SCA.

Environmental Factors and Disease Susceptibility

Environmental influences play a significant role in modulating the clinical course and complications associated with sickle cell anemia (SCA), adding layers of complexity to the disease landscape. Geographical variations, climatic conditions, prevalence of infections, and socio-economic factors intricately interact to impact disease susceptibility, severity, and access to healthcare resources for individuals affected by SCA.Geographical disparities in disease prevalence are evident, with regions historically characterized by a higher incidence of malaria demonstrating a higher prevalence of the sickle cell trait due to the protective effect against severe malaria in heterozygous

individuals. Conversely, in regions with limited access to healthcare and resources, the burden of SCA is amplified, leading to higher morbidity and mortality rates. The discrepancy in healthcare infrastructure and availability of specialized care significantly influences disease management and outcomes [40].Climatic variations also exert notable effects on disease manifestation. Extreme temperatures and dehydration are known triggers for vaso-occlusive crises, one of the hallmark complications of SCA. Additionally, exposure to high altitudes with lower oxygen tension exacerbates symptoms, underscoring the environmental sensitivity of the disease.The prevalence and impact of infectious diseases, such as bacterial infections or viral illnesses, further complicate the clinical course of SCA. Individuals with sickle cell disease, especially those with functional asplenia, exhibit increased susceptibility to certain infections, leading to higher morbidity rates. Access to preventative measures, timely medical interventions, and comprehensive healthcare are crucial in mitigating the burden of infections among individuals with SCA [41].Moreover, socio-economic factors significantly influence disease outcomes. Socioeconomic disparities may limit access to healthcare services, including specialized care and disease management resources, leading to disparities in health outcomes among individuals affected by SCA.Recognizing the profound impact of environmental determinants on disease susceptibility and severity emphasizes the necessity of comprehensive care approaches that address these multifaceted influences. Strategies focusing on preventive healthcare measures, access to specialized care, patient education, and advocacy for improved healthcare resources in regions with a high prevalence of SCA are crucial in ameliorating the burden of this complex disorder. Integrating these considerations into tailored care plans fosters a holistic approach to managing SCA and improving the quality of life for affected individuals.

Lifestyle Choices and Disease Management

Lifestyle choices constitute an integral aspect of disease management in individuals affected by sickle cell anemia (SCA). Balanced nutrition, hydration, physical activity, stress management, and psychosocial well-being significantly impact disease severity, frequency of complications, and overall quality of life for individuals navigating the challenges of SCA [42].A well-balanced diet rich in essential nutrients plays a crucial role in managing SCA. Adequate hydration is essential to maintain proper blood circulation and prevent dehydration-induced sickling of red blood cells. Consuming a diet abundant in fruits, vegetables, lean proteins, and whole grains, while avoiding dehydration and excessive intake of foods that can trigger inflammation, contributes to better health outcomes for individuals with SCA [43].Regular, moderate physical activity, tailored to individual capabilities, promotes cardiovascular health, enhances circulation, and contributes to overall well-being. However, individuals with SCA should balance physical activity with adequate rest to prevent fatigue and avoid triggering vaso-occlusive crises.Stressful events and emotional distress can precipitate or exacerbate SCA-related complications. Implementing stress reduction techniques such as mindfulness, relaxation exercises, and stress management strategies can help mitigate the impact of stress on disease symptoms and crisis frequency [44].Social and emotional support systems are invaluable for individuals living with SCA. Support groups, counseling services, and educational programs not only offer emotional support but also provide opportunities for sharing experiences, enhancing coping mechanisms, and fostering a sense of community among individuals affected by the condition [45].Adherence to prescribed medications, including folic acid supplements and medications aimed at managing pain or preventing complications, is crucial for disease management. Consistent adherence to prescribed treatment regimens helps minimize the frequency and severity of crises and reduces the risk of complications [46].Empowering individuals and families with knowledge about SCA, including symptom recognition, crisis management techniques, and the importance of regular medical follow-ups, is pivotal in improving self-care and optimizing disease management.Integrated care models that encompass medical management, patient education, and multidisciplinary support services are pivotal for holistic disease management. Specialized clinics and healthcare teams familiar with SCA provide tailored care plans, addressing the diverse needs of individuals living with the condition [47].Embracing a balanced lifestyle, coupled with access to comprehensive care and support services, forms the cornerstone of effective disease management in SCA. By integrating lifestyle modifications into individualized care plans, healthcare providers can empower individuals affected by SCA to better manage their condition and improve their overall quality of life.

Conclusion:-

The intricate interplay between genetic predisposition, environmental influences, and lifestyle choices intricately shapes the landscape of sickle cell anemia (SCA), underscoring the complexity and multifaceted nature of this hemoglobinopathy. As a hereditary disorder rooted in genetic mutations within the HBB gene, SCA presents a diverse clinical spectrum influenced not only by the primary genetic defect but also by a myriad of modifying genetic factors.Genetic modifiers, such as fetal hemoglobin levels and coinheritance of other genetic variants,

contribute significantly to the phenotypic variability observed among individuals with SCA. Understanding these genetic intricacies not only elucidates disease pathogenesis but also informs targeted therapeutic interventions aimed at modulating disease severity and improving outcomes.Environmental factors, including geographical variations, climatic conditions, prevalence of infections, and socio-economic disparities, exert profound influences on disease susceptibility and access to healthcare. Recognizing the impact of these environmental determinants highlights the necessity of tailored interventions and healthcare policies aimed at mitigating disparities and improving healthcare access for individuals affected by SCA.Furthermore, lifestyle choices encompassing balanced nutrition, hydration, physical activity, stress management, and psychosocial support constitute integral components of disease management. Integrating these lifestyle modifications into comprehensive care plans empowers individuals to better manage their condition, minimize complications, and improve their overall well-being.

References:-

1. Pecker LH, Little J. Clinical manifestations of sickle cell disease across the lifespan. Sickle cell disease and hematopoietic stem cell transplantation. 2018:3-9.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):2244-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-1.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-7.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
10. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. Newport International Journal of Scientific and Experimental Sciences 4(2):20-29.https://doi.org/10.59298/NIJSES/2023/10.3.1111
11. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41
12. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research. 2023; 6(1):2768-0487.
13. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-9.
14. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48): e36462.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students of The University of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023; 1:1-7.
18. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-5.
19. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-3.
20. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-8.

21. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-34.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-5.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants in the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018; 3. Available from: https://symbiosisonlinepublishing. com/hematology/hematology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
26. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2023;3(1):1-6.
27. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-7.
28. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
29. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-4.
30. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-3.
31. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-5.
32. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-5.
33. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-3.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. Paripex - Indian Journal of Research, 2015; 4(6): 258-259
36. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-5.
37. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
38. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michaelokpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-50.
39. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
40. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100(9):1108.
41. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, Savio J, Sethuraman N, Madan S, Shastri P, Thangaraju D. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerging infectious diseases. 2021;27(9):2349.
42. Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease---A special nutritional consideration. Nutrition & metabolism. 2016;13(1):1-2.

43. Roychowdhury D. Mindfulness practice during COVID-19 crisis: Implications for confinement, physical inactivity, and sedentarism. Asian Journal of Sport and Exercise Psychology. 2021;1(2-3):108-15.
44. Anurogo D, Yuli Prasetyo Budi N, Thi Ngo MH, Huang YH, Pawitan JA. Cell and gene therapy for anemia: Hematopoietic stem cells and gene editing. International journal of molecular sciences. 2021;22(12):6275.
45. Bellos I, Pergialiotis V, Loutradis D, Papapanagiotou A, Daskalakis G. The role of hemoglobin degradation pathway in preeclampsia: A systematic review and meta-analysis. Placenta. 2020; 92:9-16.
46. Geethakumari K, Kusuma YS, Babu BV. Beyond the screening: the need for health systems intervention for prevention and management of sickle cell disease among tribal population of India. The International Journal of Health Planning and Management. 2021;36(2):236-43.
47. Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Frontiers in physiology. 2020; 11:435.